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Tyrosinase-like Activity of Several Alzheimer’s Disease Related and Model Peptides 
and their Inhibition by Natural Antioxidants  
Kashmir Singh Juneja 
 
ABSTRACT 
 
 
 
Neurodegenerative diseases are associated with loss of neurons ultimately leading 
to a decline in brain function. Alzheimer’s disease (AD) is considered one of the most 
common neurodegenerative disorders that affects 16 million people worldwide.  The 
cause of the disease remains unknown, although significant evidence proposes the 
amyloid β-peptide (Aβ) as a potential culprit.  The binding of Cu2+ by the soluble 
fragments of Aβ have shown to form Type-3 copper centers and catalyze the oxidation of 
catechol-containing neurotransmitters.  Furthermore, the use of flavonoids as antioxidants 
to slow or inhibit the neurotransmitter oxidation has suggested further health benefits 
with their consumption.  A structure-function correlation is also made between the 
flavonoids and their reactively with Cu2+-Aβ.  Mechanistic insight into the binding of 
catechol and dioxygen within the tyrosinase-like mechanism are made using a 
metallopeptide modeling the active site of the metzinicins. 
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Chapter One  
 
 
Introduction 
 
 
Enzymes 
 
Enzymes are essential proteins that have the ability to regulate and govern 
numerous reactions required for life.  They serve as biological catalysts, reducing the 
energy barrier in a reaction.  The catalytic proficiency is further enhanced by an 
enzyme’s ability to be substrate specific. In general, enzymes can be categorized on the 
basis of the type of reaction in which they perform.  Examples include oxidoreducatses, 
hydrolases, and transferases. 
The catalysts that fall under the oxidoreducatase category are involved in redox 
reactions.  These redox reactions involve the transfer of electron(s) from one species to 
another.1 Redox reactions are involved extensively in industrial application, humus 
degradation, and are essential for life on this planet.  Biological systems use these 
oxidoreductases in anabolism, catabolism, protective, and energy sublimentive 
functions.2  Being that the inside of the cell is under reductive conditions, these enzymes 
are used to regulate and specify when and where a redox reaction takes place.  
In biological systems, constitutes formed are sometimes the result of several 
enzymes.  Whether the product is modified or the enzyme is regulated, it is usually a 
cascade of reactions that is involved in synthesizing the necessary biological components.  
Hydrolases are another class of enzymes that activate a water molecule to serve as a 
nucleophile in a substrate-specific bond cleavage.2  These hydrolytic enzymes are further 
classified on the basis of their substrate specificity.  An example is endopeptidases which 
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cleave peptide bonds within a peptide or protein at specific locations other then C and N-
terminal domains.  The structure of the protein, specifically the active site, controls the 
specificity of the enzyme.  In many enzymes, metals ions can be found within the active 
site to assist in catalysis. 
 Transition metals are excellent Lewis acids that have the ability to carry a charge 
and still contain a high electron affinity.3  In an effort to continue catalysis, metal ion(s) 
undergo a degree of mobility by making slight changes in its coordination during a 
reaction.  The differences in metal ions allow each to prefer particular geometries and 
types of chemistry.3  Table (1-1) summarizes information about several well-known 
metalloenzymes. 
Table 1-1.  Information on some metalloenzymes. 
 
Metalloenzyme Metal 
Ion(s)
Occurrence Function 
Reverse 
Transcriptase3 
Zn Human 
immunodeficiency 
virus (HIV) 
Transcribes ssRNA into dsDNA 
Tyrosinase3 2 Cu Plants and Animals Hydroxylation and oxidation of 
phenol 
Lipoxygenase3 Fe Animals Catalyse the dioxygenation of 
polyunsaturated fatty acids 
Methionine 
aminopeptidase3 
2 Co Bacteria to Animals Removal of N-terminal 
methionine 
Urease3 2 Ni Jack Bean and 
bacteria 
Hydrolysis of urea to ammonia  
Mn-catalase3 2 Mn Prokaryote Decomposition of  
2 H2O2 Æ 2 H2O + O2 
Bromoperoxidase3 V Some brown & red 
marine algae 
Defensive Mechanism 
Chromodulin4 
 
Cr Human Unknown, possible insulin 
signaling 
DMSO reductase3 Mo Bacteria Dimethyl sulfoxide to dimethyl 
sulfide 
Acetylene 
hydratase3 
W Pelobacter 
acetylenicus 
Hydration of acetylene to 
acetaldehyde 
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Metzincins 
 
The function of a metalloenzyme can be related to the transition metal ion(s) 
within its active site.  Of the transition metals, zinc is one of the most readily available to 
biological systems, ranging from 10-11 to 10-3 M in various portions of a cell.3  Zn(II) ion 
has the electronic configuration of [Ne] 3d10, lacking both spectroscopic and magnetic 
properties.  Like many of the first row transition metals, zinc is often found in divalent 
state (Zn2+) because of the loss of the 4s2 electrons.  When considering divalent cations, 
Zn2+ is an excellent Lewis acid, second only to Cu2+.3  The unique properties of Zn2+ also 
include extremely flexible coordination geometry extending, from 4 to 6 coordination. 
The most common ligands for Zn2+ are thiolate, imidazole, water, and carboxylate.  The 
Zn2+ found in metalloenzymes can serve a structural role or be involved in the reaction.  
For example, the Zn2+ in Cu,Zn-superoxide dismutase serves a structural role that 
stabilizes the protein.3  In other cases Zn2+ is involved in reactions, where in the 
metalloenzymes most always perform hydrolysis.  The classification of these 
hydrolytically active Zn2+ enzymes is based on the ligands coordinated to the metal ion 
and the substrate specificity.  
For the past two decades, several large groups of Zn2+-containing enzymes have 
received much attention because of similarities in their structure and distinctive location.  
The following groups have been classified as zinc endopeptidases: astacins, adamalysins, 
serralysins, matrixins.5  These endopeptidases contain a common α-helical Zn2+ binding 
motif (HEXXHxxGxxH) and a distant methionine turn (Figure 1.1).  It is because of these 
similarities that all of these families have been grouped into one super family called the 
metzincins.5  Despite their common structure, the metzincins have been found in  
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 numerous locations including caryfish digesitive fluid, sea urchin embryos, and snake 
vemon.5,6  In the metzincins, the metal is coordinated by 3 His side chains and a water 
molecule which is H-bonded to the Glu in the motif.5  Most recent evidence reveals a 
distant Tyr after the Met-turn in astacin, which stabilizes the enzyme-substrate complex 
through H-bonding and relieves steric hindrance.7  In addition, several studies have 
shown accelerated hydrolytic activity upon substitution of the native Zn2+ with Cu2+ or 
Co2+.7,8   
 It is evident through the properties and abundance of Zn2+ that this unique 
transition metal is one of the most important in biological systems.  The flexibility and 
ligand exchange rate haveforced nature to develop a dynamic scheme of delivery of this 
precious metal.3 Metal substitution experiments have postulated nature’s use of Zn2+ 
instead of another transition metal because of its inertness in redox chemistry. 
 
 
 
Figure 1-1:  Diagram of the zinc environment in the metzincins.5 
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Copper-Containing Enzymes 
 
Copper-associated chemistry is very rich in nature.  Exceeding all other transition 
metals, Cu2+ is a very effective divalent ion for binding organic ligand molecules.3  The 
high electron affinity makes it a valuable asset in biological redox chemistry. Several Cu-
containing enzymes can bind and activate small molecules such as O2.3  It is the affinity 
for these molecules and large redox potential that has forced nature to developed 
specialized transport systems to maintain homeostasis and limit free Cu2+ to 10-18 M in 
the human body.9  
To replenish the body, it is recommended to consume 0.9 mg of copper per day.9  
Copper is absorbed mainly in the small intestine and transported to the liver.  Here, 
transporters and chaperons deliver the metal to various locations in the body.  One of the 
main transports is human copper transport protein (hCtr1). 9   Together with the influx of 
potassium (K+), copper is taken up and delivered to several chaperons or storage 
structures such as the metallothionein pool.3  The chaperons in turn supply Cu to proteins 
like superoxide dismutatse, amyloid precursor protein (APP) dopamine β-hydroxylase, 
and tyrosinase.  The role of many Cu enzymes is O2 activation followed by oxidation of a 
substrate.10  The mechanistic differences within Cu-proteins are due to the protein 
structure, the number of Cu ions, and the coordination chemistry.  
The copper within proteins is usually limited to one of three types of coordination.  
Each copper protein can be categorized as Types I-III.  Type I copper proteins are well-
known for their intense blue color and consist of blue Cu-proteins and blue Cu-
oxidases.11 The blue Cu-proteins contain one copper ion coordinated by two histidines, 
one cystein, and one loosely coordinated methionine in a trigonal or trigonal bipyrimadal 
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conformation.11  An example of a Type I copper protein is the electron transfer protein 
plastocyanin in photosynthesis.  The active site of Type II copper protein is usually 
coordinated by both nitrogen and oxygen-containing ligands in a tetragonally distorted 
configuration.11  A well-known Type II copper enzyme is the radical scavenging Cu/Zn-
superoxide dismutase.  The third group of copper proteins are the EPR silent Type III 
copper proteins.  These copper proteins contain two copper ions as a dinuclear center 
coordinated by six histidine residues.11    One of the best known examples is tyrosinase.   
To date, tyrosinase is considered one of the most well studied multicopper 
oxygenases.  Found widely in living systems, tyrosinase is responsible for the preliminary 
steps in the synthesis of melanin.12  Like all Type III copper proteins, tyrosinase utilizes 
its dinuclear center to bind dioxygen.  Following the subsequent activation of O2, it 
hydroxylates and oxidizes the phenolic substrate to yield the ortho-quinone product 
(Figure 1-2).12  The rates for the oxidation (107 s-1) is ten thousand times that of the 
hydroxylation (103 s-1).11 To determine the mechanism and its intermediates, nitrogen-
based model systems have been used extensively.13    
 7
 
The reaction at the dinuclear center of tyrosinase begins with the binding of 
dioxygen, converting the deoxy into the oxy form of the dinuclear center.  Monophenol 
then binds to one of the copper centers, allowing for it to be oriented for ortho 
hydroxylation.  The hydroxylation is believed to go through one of three intermediates 
OH
OH
NH3+
COO-
Tyrosinase
O2
H 2O
O
O
NH3+
COO-
NH2+O
O COO-
NH2+OH
OH COO-
NH2+O
O
L-dopa Dopaquinone
Leucodopachrome
Dopachrome
Eumelanin
NH3+
COO-
OH
Tyrosinase
5,6-dihydroxyindole
 
Figure 1-2:  Scheme depicting tyrosinase activity in the production of melanin.12 
 8
(Figure 1-3).11  One intermediate involved the oxygen bridge cleavage prior to attack, 
resulting in the formation of a binuclear Cu3+.11  The second is the breakage of the 
oxygen bridge with the attack.11  And lastly, is a possible aryl peroxide intermediate.11  
The resulting diphenol is bound to the “met-D” center (Figure 1-4), allowing for a two-
electron oxidation to form the o-quinone.  In addition to the monophenolase activity, 
tyrosinase can oxidize catechol (diphenols) directly.  Both the met and oxy forms of the 
dinuclear center can bind and promote the oxidation of catechol.  The reaction continues 
in this cycle until the substrate has been depleted or the enzyme is inhibited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O N
N
O
O
Cu
3+
N
N N N
Cu
3+
N
N
Cu
2+
O
O
Cu
2+
N
N N N
O
O
O
O
Cu
2+
N
N
N
N
Cu
2+
N N  
 
 
 
Figure 1-3:   Three proposed intermediates for the hydroxylation of phenol by tyrosinase.11   
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The intermediates and mechanism for tyrosinase were solved using various 
synthetic metal complexes as model systems.  The structure of these complexes varies but 
generally contain N-based functional groups such as amine, pyridyl, pyrazolyl, and 
imidazole.14  Through the use of numerous spectroscopic techniques and low-temperature 
experiments, a number of plausible Cu:O2 intermediates have been found.10  However, 
N
N
Cu
2+
O
O
Cu
2+
N
N
N
N
Cu
2+
O
O
Cu
2+
N
N
O
O O N
N
Cu
2+
OH
Cu
2+
N
N
OH
H
+
N
N
Cu
+
H
+
O
O
H2 O
O2
O O N
N
Cu
2+
OH
Cu
2+
N
N
O
OH
OH
O
O
H2 O
H
N
N
Cu
2+
OH
Cu
2+
N
N
OH
OH
Cu
+
N
N
Oxy-T Oxy
met-D deoxy
+
oxy-D
H2 +
+
+3
met
H2 +
Monophenolase Cycle
Diphenolase Cycle
 
Figure 1-4:  Proposed mechanism for tyrosinase.11 
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these model systems have been shown to contain reduced tyrosinase activity.  The 
modeling of active sites for activity and binding is an ever growing trend that extends to 
far beyond just Type III copper proteins.15 
 
Amyloid-β and Alzheimer’s Disease 
 
Through advances in modern medicine, the duration of life has been extended by 
eliminating or postponing various human diseases.  Unfortunately, with the average life 
span almost doubling from the 19th century there has been a significant increase in aging-
related illnesses.16 Neurological disorders such as Alzheimer’s, Parkinson’s, and 
Huntington’s disease, have caused increased concern for the ever-growing number of 
victims. The most common neurodegenerative disease is Alzheimer’s (AD), affecting 
near 4.5 million Americans.17  With only 10% of the cases being familial AD, the 
majority of the occurrences are sporadic and currently unpredictable.17 In general, a 
neurodegenerative disease is associated with the accumulation of misfolded or 
fragmented protein that affects normal neuronal function.9 
 AD is a progressive neurodegenerative disease that causes memory and motor 
skill loss. There are three hallmarks associated with AD which are believed to be 
responsible for the loss of neuronal function, located primarily in the hippocampus and 
cortex: (a) accumulation of neurofibrillary tangles composed of the hyperphosporylated 
microtububle-associated tau protein (p-tau), (b) insoluble plaques formed from the 
amyloid-β peptides (Aβ), and (c) ramped loss of neurons.9,18  Even though the exact 
cause of AD is still unknown, many have hypothesized an amyloid cascade leading to all 
three of the hallmarks. 
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 Even with slight variations, it has been agreed upon that the abnormal processing 
of the transmembrane amyloid precursor protein (APP) causes an increase in the 
production of Aβ.11,17  This overproduction is believed to affect synapses, causing altered 
ionic and enzymatic homeostasis resulting in tangles, plaques, and ultimately cell death.9 
The order and location of cleavage by three secreatases (α, β, γ) determine whether the 
product will be considered amyloidogenic or nonamyloidogenic.9 The nonamyloidogenic 
pathway begins with the α-secreatase cleavage followed by a γ-secreatase forming a 
shorter more soluble fragement of Aβ.9   The amyloidogenic pathway is initiated by β-
secreatase followed again by γ-secreatase.9  The fragments of APP following cleavage 
range from 16-42 amino acids in length (Figure 1-5), with the insoluble  Aβ40 and  Aβ42 
believed to have the largest effect on neuronal cell loss.9,18 
 
In addition to the accumulation of protein fragments,  postmortem studies have 
reported millimolar amounts of Zn2+, Cu2+, and Fe3+ within the amlyoid plaques.17  The 
findings of redox-active metals have fueled the hypothesis of reactive oxygen species 
(ROS) as a major contributor to the degradation of brain function in AD.  The ROS 
species normally generated by the body are used for degradation and defense purposes.2 
The body regulates ROS by both SOD and catalase.  The hypothesis that ROS is part of 
AD is well justified as non-regulated accumulation of redox active metal has led to other 
DAEFR5HDSGY10EVHHQ15KLVFF20AEDVG25SNKGA30IIGLM35VGGVV40 IA42 
Figure 1-5:  Amino acid sequence of Amyloid-β peptides (Aβ).  
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illnesses such as Wilson’s Disease (WD).9  The metal-centered generation of ROS is 
believed to be consistent with the Fenton and Haber-Weiss reactions shown below.9  
 
 
 
Studies have shown that APP is an active participant in copper homeostasis, with 
significant loss of this protein showing elevated levels of free Cu2+.9 Not surprising is that 
Aβ has also shown to chelate metal with a high affinity.19  Through the use of NMR, the 
binding site for the metal has shown to be three His within the first 14 amino acids.20 
Additional studies have shown the possible dimerization and coagulation of Aβ to begin 
at amino acid 17-20.21  Although much emphasis has been put on Aβ40,42 , numerous 
structure studies are focused on all of the Aβ and possible ways to inhibit its formation. 
To date, treatments for AD include metal chelators and acetylcholine esterase 
inhibitors.  Unfortunately there are many side effects associated with the metal chelators, 
specifically due to the chelation of “needed” metal ions.  The binding of redox-active 
metals to solvent-exposed peptide domains has raised the issue of possible ROS 
generation in AD.  This emphasizes the development of bioavailabile metal chelators or 
the use of antioxidants to scavenge ROS.  
Flavonoids  
 
In ancient China, there had been evidence of the use of antioxidants as a remedy 
to cure human illness.  Of these antioxidants, a group of phenolic plant constituents 
encompass a major portion of those consumed around the world for their potential 
benefits.  To date, there are over 6000 of these compounds known as flavonoids.22  
O2- + H2O2 Æ OH- OH• + O2   (Haber-Weiss reaction) 
Mn+ + H2O2 Æ OH- + OH· + M(n+1)+  (Fenton reaction) 
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Several clinical studies have been done concerning the possible protection against cancer, 
cardiovascular, and neurodegenerative diseases.23,24 They have been further used for their 
potential anti-fungal, anti-microbial, and anti-radical properties.22  
Flavonoids have gained much attention over the years because of their potent 
antioxidant properties and bioavailability. The structural differences of the flavonoids, 
although subtle, have shown to remarkable change their bioactivity.25 It is these 
differences that allow the flavonoids to be divided into subcategories.  The general 
structure consists of two benzene rings (A and B) linked though a tetrahydropyran or α-
pyrone ring (C).22  Flavones (e.g. apigenin) contain a double bond at the 2-3 position, 
while flavanones (e.g. narigenin) are staturated at this position. A double bond at the 2-3 
position and a hydroxyl, methoxy, or sugar at the 3 position represents the flavonol 
category (e.g. quercetin, fisetin).  Dihydroflavonols contain a hydroxyl group at the 3 
position and is absent of the 2-3 double bond.  The catechins lack the ketone functionality 
in the C ring and contains hydroxyl groups at 3, 3’, and 4’ positions.  Many other 
classifications exist for flavonoids that contain further unsatutartion, hydroxylation, 
epoxidation, and sugar modification. Table 1-2 describes the structure of several well 
studied flavonoids. 
 The quantity of each group of flavonoids depends on the kind of plant, climate, 
and location the plant is found.  For example, several categories are found in higher 
amount in citrus, while others are found in green-leaf vegetables.22 Although there is an 
abundance of flavonoids within the diet, their protective properties are only good as they 
are absorbed.  Several flavonoids have better absorptive properties then others.  It has  
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Flavonoids Classification R1 R2 R3 R4 R5 R6 2-3 Alkene 
4 
Ketone 
(-)-Epicatechin Flavan-3-ol H OH OH OH OH H - - 
(-)-Epigallocatechin 
Gallate Flavan-3-ol Gallate OH OH OH OH OH - - 
Fisetin Flavonol OH H OH OH OH H + + 
Quercetin Flavonol OH OH OH OH OH H + + 
Taxifolin Dihydroflavonol OH OH OH OH OH H - + 
Apigenin Flavone H OH OH H OH H + + 
Narigenin Flavone H OH OH H OH H - + 
Hesperetin Flavanone H OH OH OH OCH3 H - + 
Rutin Flavonol glycoside 
Rutinose 
 OH OH OH OH H + + 
 
 
been shown that lactase and β-glycosidase can cleave the glucoside portion off the sugar 
derivatives of flavonoids.22 It is the effects following absorption that has increased the 
interest in the natural polyphenols.  
With numerous illnesses and disease being associated with ROS, the antioxidant and 
antiradical properties of flavonoids have become the center of attention. For a compound 
to be considered a strong antioxidant it must inhibit oxidation reactions and/or the 
production of radicals at a low concentration compared to the oxidizable substrate.  
Table 1-2:  The classification and structure of several well studied flavonoids. 
A
B
C
3'
5'
4'
R 3 O
R 1
O
R 5
R 4
R 6
R 2
7
5  4
3 
2
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Furthermore, the radicals formed by flavonoids must be stable enough not to continue in 
as a chain propagating radical.  These properties associated with flavonoids have been 
used in conjunction with other molecules to further stabilize or complement the 
flavonoids bioactivity.26 
 
Green Tea  
 Believed to have originated some 3000 years ago in ancient China, tea is now one 
of the most consumed beverages in the world.27  The leaf extract of the plant Camellia 
sinensis, also known as tea, have shown to be rich in antioxidant polyphenols, ascorbic 
acid, and trace elements Cr, Mn, Se, and Zn.27  Depending on the species, season, and 
extent of fermentation, the amounts of these health-beneficial compounds can vary 
significantly.  The trace elements Mn, Se, Zn are directly involved with a number of 
enzymes that reduce oxidative damage.3  Biological systems use Mn as a constituent for 
Mn-superoxide dismutase.  Additionally, Se serves as a cofactor for glutathione 
peroxidase, allowing for the removal of peroxide radicals.3  When considering green, 
oolong, and fermented teas, green tea has shown to contain a higher content of catechins 
and other hydroxylated phenols.27,28  Within green tea, the general trend of quantity of 
green tea catechins (GTC) is (-)-epigallocatechin gallate (EGCG) > (-)-epicatechin gallate 
(ECG) > (-)-epicatechin (EC)  ≥ (-)-epigallocatechin  (EGC) >> (+)catechins.27,28  
Green Tea Catechins (GTC) 
 The GTCs are similar in structure, differing only by as many as 2 substitutions 
(Figure 1-6).  The structure of ECG and EC differ only by a gallate present on position 3.  
EGCG and EGC differ only by an additional hydroxyl group on the B ring in position 5’.  
Despite these small differences, studies have shown them to differ in various types of 
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bioactivity and availability.  Like many flavonoids, the GTCs have been shown to exhibit 
potential protective effects against cardiovascular disease, cancer, and neurodegenerative 
disease.28  
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Figure 1-6:  The green tea catechins (A) Epicatechin (EC), (B) Epigallocatechin 
(EGC), (C) Epigallocatechin Gallate (EGCG). 
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GTCs have gained popularity as they have been demonstrated to show metal 
chelating, free radical scavenging, protein interaction, and transcription factor regulatory 
abilities.23  Specifically, several links have been made between GTCs and diseases 
involving ROS.  Following their reactions with free radicals GTCs form a number of 
dimers and seven member anhydride rings.29   In comparison with the body’s natural 
radical scavengers, EGCG can increase cell survival similar to that of catalase in ROS 
affected cells.30  Structurally, implications have been made on the advantage of the 
trihydroxybenzene and gallate moieties to enhance the antioxidant and metal chelation 
abilities.23,28  In addition to its chemical properties, the brain-permeability of GTCs may 
offer beneficial effects in several neurodegenerative diseases.  A recent study on 
Alzheimer’s disease has linked EGCG with APP processing.31  It was shown in vivo and 
in vitro that EGCG enhances the activation of the α-secretase and inhibits β-secretase 
activity, leading more toward a nonamyloidogenic pathway.31  
 Despite their reactivity, there is much concern over the stability of GTCs.  
Following an oral dose of 100mg of GTCs, only 9-10ug/ml will be absorbed.26 The 
absorption deficiency may be due to the change from the acidic stomach to the alkaline 
blood.26  In basic conditions, the trihydroxybenzene is probably more susceptible to 
oxidation and the gallate is hydrolytically cleaved to form gallic acid.26  Despite these 
absorption problems, green tea remains one of many good sources of flavonoids. 
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Citrus Flavonols  
 
Citrus is a flowering plant genus found in the Rutaceae family.   It includes fruits 
such as oranges, grapefruits, and lemons.  There is an annual production of 80 million 
tons of citrus fruits world wide.32 These fruits are known for their characteristic scent and 
sharp taste.  They are rich both in vitamins and flavonoids. Citrus has utilized these 
compounds to develop pigmentation and protection from insects in addition to ROS.22   
Studies have linked the components in citrus to prevention of cardiovascular disease, 
cancers, and allergies.33  Depending on the fruit, citrus can be an excellent source of 
many flavonoids.  Three structurally similar polyphenols found in citrus are quercetin, 
fisetin, and taxifolin, which vary in medicinal effect. 
Quercetin, Fistein, and Taxifolin 
In general, there are several presumed structural requirements for flavonoids to 
have good antioxidant/antiradical properties.  The structural requirements include: a 
catechol/polyphenol B ring, 2-3 double bond, abundance of free hydroxyl groups, and 
specifically the 3-hydroxyl group.34 
Quercetin is the most common flavonol in the human diet.  There is an abundance 
of quercetin in onions, fruits, teas, and red wine.22 Variations of quercertin are found 
naturally, having one or more sugars bound at the 3 position.  Studies have shown these 
sugar moieties assist in the absorption of quercetin.22  Like many flavonoids, queretin 
bind metal in addition to scavenging free radials.22,35 Fisetin is a less common flavonol, 
found in various fruits and vegetables.  It differs from quercetin in that it lacks a 
phenolate.  The desaturation of quercetin at the 2-3 position yields taxifolin, appropriately 
known as dihydroquerctein.  Taxifolin is considered a dihydroflavonol and is also found in 
some fruits and vegetables.34   
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Many studies have compared the flavonoids based on their level of antioxidant and 
antiradical activity.  In a study published by Oleszek et al.(34) the antioxidant properties 
were found to increase with the presence of the 2-3 double bond (i.e., Quercetin > Fisetin 
>> Taxifolin).  They also showed the antiradical properties were affected by the presence 
of the 3-OH and not the 2-3 double bond (Taxifolin > Quercetin > Fisetin).34  As there 
has been some debate over the “best” flavonoid, it generally agreed upon that the 
combination of several antioxidants would yield the best antioxidant/radical properties. 
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Figure 1-7:  Structure of flavonols qercetin (A), fisetin (B), and dihydroflavonol 
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Vitamins 
 
Once thought to require an amine functional group, they were termed “vital 
amines” (vitamine). Over the years, structural evidence revealed the lack of the amine in 
many vitamines, resulting in the loss of the “e” (vitamin).36 Most vitamins are obtained 
through the diet and are classified on either being water (B and C) or fat (A, D, E and K) 
soluble.  These compounds are found in abundance in human diet, with fruits and 
vegetables being excellent sources.  Studies have shown that many vitamins have 
excellent antioxidant properties and are directly involved in many human illnesses.36 
Vitamin B6 
 Considered to be 1 of 8 components of the vitamin B complex, vitamin B6 is 
found in three structurally distinct forms: pyridoxal, pyridoxine, pyridoxamine.  An 
enzyme known as pyridoxal kinase converts each of the three in the active form of 
vitamin B6, pyridoxal 5’-phosphate.37 The body utilizes the active form as a cofactor for 
over 140 enzymes.37 Some of which are involved in amino acid and monoamine 
neurotransmitter synthesis.38  A deficiency in vitamin B6  has been shown to lead to 
insufficient insulin and altered hormone production.38 The recommended daily intake is 2 
mg, which is easily obtained from various vegetables, fish, and non-citrus based fruit.38  
In addition to its regulatory roles vitamin B6 has also been shown to serve as a potent 
antioxidants.39  Studies have suggested that components of vitamin B6 inhibit the product 
of radicals and serve as quenchers for singlet oxygen.39  
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Ascorbic Acid  
 Being the most abundant soluble antioxidant in plants, L-ascorbic acid (AsA) 
(aka. Vitamin C) (Figure 1-9) has become increasingly consumed because of its proposed 
health benefits.40 At risk of diseases such as scurvy, AsA is considered essential in the 
human diet.  The body uses AsA as radical scavenger, calcium regulator, and as a 
cofactor for multiple enzymes, some involved in collagen synthesis.  It is the 
antioxidant/antiradical properties associated with AsA have believed to be responsible for 
its contribution to the prevention of numerous chronic diseases.40   
Through consumption of beverages such as green tea, one can easily obtain the 
recommended daily intake of 30-110 mg/day.40 In addition to its health benefits, AsA 
effect on the absorption of other biological components has also been measured.26  For 
example, the low absorption of GTCs is thought to be because of its oxidative 
breakdown. Results have shown AsA to serve as a reductant that can protect GTCs and 
potentially increase their total absorption.26  Although the overall effect of one compound 
N CH3
OH
NH2
OH
                    
N CH3
OH
NH2
Phosphate
  
 
Figure 1-8: Structures of pyridoxamine and pyridoxamine-5’-phosphate 
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can be significant, it is usually thought that a combination of antioxidants (e.g. flavonoids 
and vitamins) can provide a more beneficial antioxidant protective effect.41 
 
Closing Remarks: 
 
When characterizing an enzyme, it is not uncommon to use model systems to 
reveal both mechanistic and structural information.  Furthermore, it is often beneficial to 
find stable enzyme mimics that exhibit high levels of activity. This thesis presents both 
modeled and natural peptides that show tyrosinase-like activity.  The former is the 
metzinicin active site and is characterized through metal binding, activity, and inhibition.  
The latter are varied fragments of Alzheimer’s disease-related amyloid-β.  Catalytic 
efficiency and mechanistic insight are obtained on amyloid through the use of 
physiologically relevant substrates.  In addition, select flavonoids and vitamins are used 
to show that the possible consumption of high content antioxidant foods can reduce 
oxidative stress caused by Aβ. These antioxidants are compared based on their overall 
effect of the Aβ tyrosinase-like chemistry.  
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Figure 1-9:  Structure of (R)-3,4-dihydroxy-5-((S)-1,2-dihydroxyethyl)furan-2(5H)-one 
(Ascorbic Acid) 
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Chapter Two   
 
Blastula Protease-10 Peptide as Tyrosinase-like Mimic 
 
 
 
 
Introduction/ Rationale 
 
 Blastula Protease 10 (BP10) is a mono-nuclear Zn-dependent endopeptidase that 
is involved in sea urchin embroyogenesis.1 The enzyme utilizes a structural motif 
(HExxHxxGxxH) and a Tyr ligand following a distant “Met turn” to coordinate the Zn2+ 
ion.  These conserved structures are found in nearly 30 different enzymes and are 
classified as “metzinicins.”2 The exact role of BP10 in embroyogenesis is still unknown.  
Furthermore, it is difficult to make comparisons to other members of the metzincins 
because each differs remarkably in localization. In a recent study, the copper derivatives 
of BP10 was prepared and have been shown to be more hydrolytically active in 
comparison to that of the native Zn-derivative.1 The binding of Cu2+ to the His rich motif 
has alluded to the possibility of additional types of Cu-chemistry.  
For years, model complexes have been prepared to characterize both 
intermediates and mechanisms for Type 3-Copper proteins, such as Tyrosinase.3,4 
Tyrosinase is an enzyme found in both plants and animals, responsible for the synthesis 
of melanin.  This enzyme is well studied partially due to its agricultural significance, 
specifically its role in the browning of food.  These model complexes tend to be nitrogen 
rich and activity is usually shown in mixed organic/aqueous solvent.3 Only in the past 
few years have begun to use model peptides to mimic enzymatic catalysis.5,6 The next 
chapter will concern the use of the metzincin motif from BP10 as tyrosinase mimic in 
aqueous media.  Metal binding and mechanistic information is alluded to by various 
kinetic experiments.  
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Experimental: 
 
Chemicals and Materials for Metal Titrations and Kinetics Assays: 
 
 The BP10 peptide was synthesized and purchased from the University of South 
Florida Peptide Center.  The identity of the 21 amino acid peptide (GIVHE IGHAI 
GFHHE QSAPD R) was confirmed with a Bruker matrix-assisted laser desorption 
ionization MALDI time-of-flight mass spectrometer.  The buffer used in all assays is 100 
mM HEPES at pH 7, with small amount of chlex resin to demetalize the solution.  EDTA 
was used in cleaning glass/plastic ware prior to usage in order to prevent metal 
contamination.  Deionized water of 18 MΩ was obtained from a Milli Q system 
(Millipore, Bedford, MA) and used for all cleaning and for preparation of stocks 
solutions. CuSO4 and ZnSO4 were used for all experiments.  All kinetic studies were run 
using a Varian CARY50 Bio-UV-Vis spectrophotometer at 293 K. 
 
Peptide Preparation 
 
The molar absorptivity was determined by monitoring the absorbance of known 
concentrations of peptide dissolved in water at 280nm for phenylalanine.  Metal 
derivatives were prepared by the addition of a known concentration of metal to achieve a 
1:1 ratio of metal to peptide.  Fresh peptide stocks were prepared and used within 24 
hours. 
 
 
Metal Binding 
 
Apo-BP10 was diluted in 100 mM HEPES at pH 7.00 to a final concentration of 
0.5 mM.  The binding of Cu2+ was monitored by titrating metal into apo-BP10 and 
collecting the spectra after each additional of metal.  Cu2+ binding was also determined 
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through oxidative activity of Cu2+-BP10 complex toward catechol.  In 100 mM HEPES 
pH 7.00 buffer, 2mM catechol, and the 2 mM o-quinone indicator 3-methyl-2-
benzothiazolinone hydrazone hydrochloride monohydrate (MBTH), activities of various 
ratios of Cu:BP10 were monitored at 500nm for the o-quninone-MBTH complex (Figure 
2-1).  Additionally, Cu2+/Zn2+ at various ratios were titrated to BP10 and the oxidation of 
catechol (conditions same as Cu2+ titration) monitored.  
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Figure 2-1: Scheme showing the binding of o-qunione indicator 3-methyl-2-
benzothiazolinone hydrazone hydrochloride monohydrate (MBTH) 
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Enzyme Kinetics 
 
 The study of the effect of changing experimental conditions on the rate of an 
enzyme-catalyzed reaction is known as enzyme kinetics.  In most studies, the initial rate, 
Vo, varies almost linearly with substrate concentration, [S] is determined. At higher [S], 
Vo response is decreased, eventually being virtually unaffected by any addition of S.  
This seemingly constant rate is considered as the maximum velocity, Vmax.  The reaction 
between the enzyme, E, and S, yields an ES complex, a necessity for the next step in 
enzymatic catalysis.   
k1
E   +   S ES
k2 E   +   P
k-1  
When the enzyme is initially introduced to the substrate, the reaction quickly 
achieves a steady state, with the ES complex remaining constant over time.  The ES 
complex then breaks down to yield a product (P) and an E that is able to catalyze another 
reaction.  The breakdown of the ES complex is used to determine Vo (Equation 2.1).   
 [ES]kV 2o =       Equation 2.1  
Experimentally it is difficult to determine [ES], making it important to consider 
alternative methods to determine Vo.   Utilizing a steady-state assumption that states the 
[ES] complex is formed and broken-down at an equivalent rate, one can derive an 
equation that can determine Vo though the use of experimentally derived parameters.  The 
rate of ES formation and breakdown can be define by equations (Equation 2.1, 2.2) 
[ES])[S]]([Ek
dt
d[ES]
t1 −=      Equation 2.2 
[ES]k[ES]k
dt
d[ES]-
21 += −      Equation 2.3 
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Where [Et] is the total enzyme concentration (both in E and ES).  Setting these 
equivalent and through some algebraic manipulation to solve for [ES], yields Equation 
2.4. 
1
12
t
k
)k(k[S]
][S][E
[ES]
−++
=      Equation 2.4  
By substituting equation 2.4 into equation 2.1, one can express the equation in terms of 
Vo (Equation 2.5). 
1
12
t2
o
k
)k(k[S]
][S][Ek
V
−++
=       Equation 2.5 
Because Vmax is defined as the maximum velocity attained after the enzyme is 
saturated (Equation 2.6), the equation to solve for Vo can further be simplified (Equation 
2.7) 
  ][EkV t2max =            Equation 2.6                       
1
12
max
o
k
)k(k[S]
[S]V
V
−++
=      Equation 2.7 
Another parameter of particular importance is the Michaelis-Menten constant 
(Km). This is usually defined as the substrate concentration that has a rate equal to half 
the Vmax.  Km is solved to give Equation 2.8. 
1
12
m k
kkK −+=       Equation 2.8 
Substituting this equation in equation 2.7 yields what is known as the Michaelis-
Menten equation (Equation 2.9) and is depicted in figure 2-2. 
 33
[S]K
[S]V
V
m
max
o +=        Equation 2.9 
 
 
Depending on the rate limiting step, specifically when k2 << k-1, Km can be used 
to represent the affinity of E to S in the ES complex. When this condition holds, Km is 
defined as the dissociation constant (Kd) (Equation 2.10), of the ES complex. 
1
1
d k
kK −=        Equation 2.10 
Since enzymes can react in fashions that the rate limiting step is not the 
degradation of ES, the first-order rate constant kcat is often used to report rates in terms of 
turnover per time (Equation 2.11).   
[E]
V
k maxcat =        Equation 2.11 
[S]
V
o
1/2 Vmax
Km
Vmax
 
Figure 2-2:  Michaelis-Menten plot. 
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Furthermore, to compare enzymes the second order rate constant kcat/Km 
(specificity constant) is used to describe the conversion of E + S to E + P. 
 Another common technique to determine kinetic parameters is through the use of 
a double-reciprocal or Lineweaver-Burk plot (Equation 2.12, Figure2-3).   
  
maxmax
m
o V
1
[S]V
K
V
1 +=       Equation 2.12 
 
The Lineweaver-Burk plot is particularly useful to distinguish types of inhibition 
patterns, including competitive, noncompetitive, uncompetitive, and mixed-type 
inhibition.   A competitive competes for the active site of an enzyme with the substrate.  
This direct competition of the inhibitor (I) can be overwhelmed by increasing amounts of 
x
1/[S]  
1/
V
o
- 1/Km
1/Vmax
Slope = Km / Vmax
 
Figure 2-3:  Lineweaver-Burk plot. 
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S.  This type of inhibition has a trend of increasing Km and relativity constant Vmax. 
Competitive inhibition is depicted by the scheme, equations, and plot in Figure 2-4. 
k1
E   +   S ES
k2 E   +   P
I  
+
E
Ki
1
Vo
=
Km
Vmax
1
[S]
( )Ki
[I]
1 + +
1
Vmax k-1
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Figure 2.4:  Graphical, schematic, and equations for competitive inhibition 
Another type of inhibition, considered noncompetitive, is when the inhibitor binds 
both E and the ES.  This type of inhibition usually has the trend of increasing Vmax and 
constant Km.   This type of inhibition is shown by the following Lineweaver-Burk plot 
trend and equations in figure (2-5). 
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Figure 2.5:  Graphical, schematic, and equations for noncompetitive inhibition 
  
 A third type of inhibition is a mix between competitive and non-competitive, 
appropriately named mixed type.  Mixed type inhibition is the same equilibrium as 
noncompetitive, with inhibitor binding at different affinities to both the E and ES 
complex.   (Figure 2.6) 
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Figure 2.6:  Graphical, schematic, and equations for mixed-type inhibition. 
 
The forth type of inhibition which is when the inhibitor binds only to the ES 
complex.  An inhibitor is considered to be uncompetitive when it influences the rate by 
binding to a location other then substrate binding site.  The binding to the ES complex is 
associated with decreasing Km and Vmax. (Figure 2.7) 
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Figure 2.7:  Graphical, schematic, and equations for uncompetitive inhibition 
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Catechol/Phenol oxidation Assays 
Using a constant Cu-BP10 concentration (2-10µM) with a 1:1 Cu to peptide ratio, 
various substrate concentrations were assayed.  The final volume of each assay is 1 mL at 
pH 7.00 100 mM HEPES and 298 K. The concentration of MBTH was kept in proportion 
with substrate concentration. Catechol was varied 0.05-1.2 mM and the MBTH-o-
quinone product was monitored at 500 nm for 3-5 mins (Figure 2-8A)   The rates were 
determined by the change in absorbance over time (Figure 2-8B).  A similar assay was 
constructed for phenol with concentrations ranging from 0.2-3.2 mM and was also 
monitored at 500 nm for o-quinone production.                    
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Hydrogen peroxide (H2O2) titration was perfomed with fixed catalyst and 
saturating amount of substrate. The conditions were similar to non-H2O2 assays described 
above. H2O2 varied from 0.25mM-12mM and the catechol/phenol-MBTH product          
(ε = 32,500 M-1 cm-1) was monitored at 500 nm. Additionally, experiments were 
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Figure 2-8: (A) The production of o-quinone from catechol monitored by the 
increase in absorption as a result of the formation of its adduct with 3-methyl-2-
benzothiazolinone hydrazone hydrochloride monohydrate (MBTH). (B) Monitoring 
the increase in absorption at 500 nm for catechol oxidation to obtain the rate. 
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preformed that varied catechol concentration at a fixed catalyst and H2O2 concentration.  
The assays preformed had a [H2O2] fixed at 0.25, 0.75, 1.5, 3.0, or 6.0 mM. 
Deuterated–phenol (d-phenol) experiments were performed under the same 
conditions as described above.  Using 10 µM Cu2+-BP10 and varying d-phenol from .4-
3.2 mM the absorbance was monitored at 500 nm.  Furthermore, under saturating 
conditions of H2O2 (20 mM), d-phenol was titrated.                 
 
Inhibition Experiments 
 
Conditions for inhibition experiments consisted of 0.5-2 µM Cu2+-BP10, pH 7.00, 
100 mM HEPES buffer, 293 K, and 1 ml total volume.  To obtain the Dixon plot, kojic 
acid was titrated into assays containing fixed catechol and MBTH concentrations 
(0.3mM).  Kojic acid concentration varied from 0.025 - 0.8 mM.  Catechol oxidation was 
then monitored at various concentrations of kojic acid (0.25, 0.05, and 0.1 mM) at 500 
nm. 
Cyanide inhibition was monitored under similar conditions to kojic acid 
inhibition.  A dixion plot was obtained by titrating cyanide into a fixed amount of 
catechol (0.3mM) and monitoring for the formation of the o-qunione. Catechol oxidation 
was then monitored at various concentrations of cyanide (0.002,0.005, 0.0035, mM) to 
obtain the Lineweaver-Burk plot.  A Dixon plot was then obtained that kept catechol, 
MBTH, catalyst, and H2O2 (0.7 mM) constant, while titrating cyanide.  Assays were then 
performed at 0, 0.015 and 0.03 mM cyanide, while varying H2O2 from 0.125-10 mM. A 
third inhibition experiment was preformed that varied catechol at various cyanide 
concentrations (0, 0.015, 0.03 mM) while keeping H2O2 under saturating condition (8 
mM). 
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Results and Discussion   
Metal Binding  
To examine the metal-coordination environment, the electronic spectrum of Cu2+-
BP10 was obtained (Figure2.5).  Upon the addition of Cu2+, there is a d-d transition with 
a λmax of 610 nm.  The spectrum is analogous to type-2 copper centers and distinct from 
aqueous Cu2+ absorbance at 820 nm.6  Furthermore the spectrum is comparable to 
published Cu2+-bound His-rich peptides.6 In order to gain further insight into the metal-
centered redox chemistry, activity was also used to confirm the Cu2+:BP10 stoichiometry.  
By measuring the activity at various equivalents of Cu2+, the resulting data saturates 
around 1:1 ligand-to-metal ratio (Figure 2.6).  The data reveals a sigmoidal pattern which 
is fit to the Hill equation yielding a Hill coefficient of 2.87.  In general, a Hill coefficient 
greater then unity indicates a positive cooperatively.  For comparsion purposes, the 
coefficient for Cu2+ binding to BP10 is equivalent to that of O2 binding to hemoglobin 
with a Hill Coefficient of 2.8.  To gain further insight into the metal-center, diluting Cu2+-
BP10 with Zn2+ would effectively silence the redox chemistry.  If the catalysis is carried 
out by a mononuclear Cu2+-center, the Zn2+ should replace the Cu2+ and result in a non-
cooperative nearly linear binding.  Figure 2.6 indicates a sigmodal relationship, yielding a 
Hill coefficient of 1.76.   This suggests the possible presence of a cooperative Cu2+ 
binding to form a Type-3 copper center during the catalysis of catechol, corroborating 
with the result in direct Cu2+ binding (Figure 2.,6 Top)  
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Figure 2.9: Electronic spectra of Cu2+-BP10 with 1 equivalent of Cu2+-BP10. 
(100 mM HEPES buffer at pH 7.0, 0.5 mM BP10)   
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Figure 2.10: (Top) Cu2+ titration to BP10 monitored with the oxidation of catechol. Fit to 
Hill equation, which yields a Hill coefficient of 2.86 ± 0.18. (Bottom) Oxidative activity 
of Cu2+-BP10  toward the oxidation of catechol as a function of the mole fraction of Cu2+ 
at a constant total concentration of Cu2+ and Zn2+. Fit to Hill equation, which yield Hill 
coefficient of 1.76 ± 0.17. (Both assays contained [BP10] = 6 µM, [MBTH] = [catechol] = 
2mM, 100 mM HEPES buffer pH 7.0, 293 K)  
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Catechol/Phenol Oxidation  
The oxidation of catechol to o-quinone is a 2-electron transfer that favors the presences of 
a dinuclear Cu2+ center.  Studies concerning tyrosinase and catechol oxidase have shown 
that once the dinuclear center is in the met form, catechol can readily bind and be 
oxidized to its quinone product.7 In the presence of O2, micromolar amounts of Cu2+-
BP10 can readily oxidize catechol and is saturated at mM amounts of substrate (Figure 
2.7),  yielding a  kcat = 4.06 s-1, Km = 0.254 mM, and a significant second-order rate 
constant of 1.60 x 104 M-1 s-1.  In terms of first order rate constant, Cu2+-BP10 is 8.57 x 
106 fold higher than the autooxidation of catechol (ko = 4.74 x 10-7 s-1) and 7.5 fold 
higher then another catechol oxidizing peptide mimic (0.531 s-1).6  
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Km               (mM) 0.254 ± .020  
Vmax           (mM/s) (1.63 ± .04) x 10-5   
kcat          (s-1) 4.06 
kcat/Km   (mM-1 s-1) 16.0 
Figure 2.11:  Cu2+-BP10 oxidation of catechol at pH 7.00 and 293K.  
[Cu2+-BP10] kept constant at 4 µM.  Table includes kinetic parameters. 
 
 47
To gain further insight into the mechanism of Cu2+-BP10, H2O2 was titrated into 
the complex with saturating amounts of catechol (Figure2.8).  The data showed a 
significant increase in rate and was saturated after mM amounts of H2O2.  The saturation 
kinetics observed for both catechol and H2O2 implies a possible bisubstrate mechnaism, 
wherein both can bind to the metal active center. To obtain apparent and  
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Km               (mM) .967 ± .188 
Vmax           (mM/s) 1.27x10-4  ± 6.12x10-6 
kcat          (s-1) 31.8 
kcat/Km   (mM-1 s-1) 32.8 
 
Figure 2.12  The effect of H2O2 on Cu2+-BP10 oxidation of catechol in the presence 
of saturating catechol (1.5mM) at pH 7.00 and 293K.   [Cu2+-BP10] kept constant at 
4µM. Table includes kinetic parameters.
 48
intensic dissociation constants for catechol and H2O2, the rates at varying amounts of 
[H2O2] holding [catechol] constant and vise versa were determined (Figure 2.9). The data 
could be fitted to a two-substrate random-binding equilibrium shown below. 
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Figure 2-13: Random bisubsubstrate equation  and equilibrium. 
 
In the equation, Kapp(H) is the apparent affinity constant for H2O2, Kapp(C) is the 
apparent affinity constant for catechol, and Kint(C) is the intrinsic affinity constant for 
catechol.  From the Hanes analysis, a secondary plot of the slope (1/Vmax) and the y-
intercept (Kapp(Substrate)/Vmax) verus 1/[Substrate] is obtained (Figure 2.10). From the 
slopes and y-intercepts of these secondary plots, the apparent and intensic dissociation 
constants can be obtained.  Using the ratios of Kapp/Kint the effect of the binding of one 
substrate on the other can be measured. If the ratio is above 1, then the binding of one 
ligand decreases the affinity for the other, below one represents an increased affinity, and 
equal to 1 indicates no effect on one another.  From the results obtained  
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Figure 2.14:   (Top Plot) The effect of the concentration of H2O2 on the first-order 
rate constant kcat toward the Cu2+-BP10 oxidation of catechol.  (Bottom Plot) 0 
(●), 0.25 (○), 0.75 (▼), 1.5 (∆), 3.0 (■), and 6 mM (□) H2O2 effect on the rate of 
catechol oxidation. Conditions at pH 7.0 and 293 K,  [Cu2+-BP10] = 2 µM. 
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Kapp(C)/Kint(C) =0.752, while Kapp(H)/Kint(H) = 1.04. From the Hanes analysis, catechol seems 
to have no effect on H2O2 binding, while H2O2 increases the affinity for catechol slightly.  
Although these results provide insight into the Cu2+-BP10 mechanism, alone they provide 
insufficient evidence to conclude the sequencal binding.   
 In addition to catechol oxidation, Cu2+-BP10 was shown to hydroxylate and 
oxidize phenol to the o-qunione product.   Phenol hydroxylation is often times 
challenging for metal-centered chemistry because it is a spin-forbidden process, inserting 
the triplet O2 into the singlet C-H bond.  Furthermore, the aerobic 
hydroxylation/oxidation of phenol is relativity slow (k0 = 4.60 x 10-8 s-1).6 Cu2+-BP10 was 
shown to significantly enhance the tyrosinase-like hydroxylation activity by 8.57 x 103 
times (kcat = 3.94 x 10-4 s-1).  The rate compared to catechol oxidation is significantly 
reduced by around 1 x 105 times, believed to be in part due to the difficult hydroxylation 
step.  To further inquire if in fact the rate determining step is the hydroxylation, d-phenol 
was used as a substrate.  The rate of the reaction remained relatively unchanged, with a 
kinetic isotope effect of only 1.27.  This result indicates that hydroxylation is most likely 
not the rate determining step of the reaction.   
 
 
 
 
 
 
 
 
 
[H2O2] mM Km (mM) Vmax (mM/s) kcat (s-1) kcat/Km (M-1 s-1) 
0 0.25 ± 0.02 (1.63 ± 0.04) x 10-5 4.06 16.0 x 103 
0.25 0.40 ± 0.06 (3.97 ± 0.20) x 10-5 19.9 49.4  x 103 
0.75 0.29 ± 0.01 (5.47 ± 0.08) x 10-5 27.4 93.5  x 103 
1.5 0.41 ± 0.04 (8.56 ± 0.26) x 10-5  42.8 103  x 103 
3.0 0.27 ± 0.03 (9.40 ± 0.35) x 10-5   47.0 173  x 103 
6.0 0.39 ± 0.08 (1.19 ± 0.78) x 10-4  59.5 149  x 103 
Table 2.1:   Kinetic parameters for H2O2 effect on Cu2+-BP10 oxidation of catechol. 
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Km (C)       (mM) 0.427
Kapp (C)    (mM) 0.321
Km (H)       (mM) 0.535
Kapp (H)    (mM) 0.558
Kapp (H) / Km (H) 1.04 
Kapp (C) / Km (C) 0.752
 
Figure 2.15: (Top) Hanes analysis of various [catechol] and secondary plot (slope ○, y-
intercept ●).  (Bottom) Hanes analysis of various [H2O2]  and secondary plot (slope ○, 
y-intercept ●).  Table includes apparent and intrinsic affinity constants for catechol and 
H2O2. 
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 Phenol d-Phenol 
Km               (mM) 1.67 ± .218  1.40 ± .176 
Vmax           (mM/s) (3.9 ± 0.2) x 10-6  (3.1 ± 0.2) x10-6  
kcat          (s-1) 3.94x10-4   3.05x10-4   
kcat/Km   (mM-1 s-1) 2.36x10-4 2.18x10-4 
 
Figure 2-16:  Cu2+-BP10 hydroxylation/oxidation of phenol (●) and  d-phenol (○) 
without H2O2.  Table includes kinetic parameters. 
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Inhibition 
 
 The results thus far have indicated that both H2O2 and catechol/phenol are 
substrates for Cu2+-BP10. Further detailed mechanistic inferences can be made by the use 
of oxygen and catechol mimics as inhibitors. A popular competitive inhibitor for Type-III 
Cu-centers is kojic acid.8 As seen in Figure 2-12, kojic acid shows to be a competitive 
inhibitor for catechol oxidation by Cu2+-BP10.  The low Ki indicates the inhibitor has 
tight binding and is relatively specific for the catalyst.   Kojic acid inhibition further 
supports the notion of the presence of a dinuclear center and that catechol binds to the 
same location as kojic acid.  
 To gain insight into the role and binding of the oxygen species cyanide was used 
as an inhibition.  Cyanide is a well-known oxygen mimic that has been used to 
characterize O2 binding sites. In figure 2-13, cyanide is used in the presence of 
atmospheric O2 while titrating catechol.  The mixed type inhibition and near equal Ki and 
Kis indicate cyanide binds to both the E and ES complex with similar affinity.  Since the 
concentration of O2 in solution is unknown and may not be at saturating conditions, the 
type of inhibition for this assay reveals only the possible presence competitive and 
uncompetitive inhibition and that cyanide can bind to the E and/or ES complex.  Another 
cyanide inhibition assay checked the inhibition in the presence of saturating conditions of 
catechol while titrating H2O2 (Figure 2-14).  The results reveal a clear noncompetitive 
pattern between cyanide and H2O2.  The inhibitor in noncompetitive inhibition binds both 
the E and the ES complex.  Being that catechol is at saturating conditions and bound first 
to E, cyanide could possibly serve as a reducing agent stabilizing and blocking Cu+ and 
thus preventing O2 from binding.  The third cyanide inhibition experiment involved H2O2  
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 [Kojic Acid] mM Km (mM) Vmax (mM/S) 
0.00 0.202 ± .016 (1.30 ± 0.03 ) x 10-5  
2.50e-2 0.344 ± .013 (1.39 ± 0.02) x 10-5  
5.00e-2 0.435 ± .041 (1.39 ± 0.05) x10-5  
1.00e-1 0.534 ± .074 (1.28 ± 0.07) x 10-5 
Ki= 0.043 mM 
Figure 2-17: Kojic Acid Inhibition- (Top) Kojic acid titration into constant [catechol] 
and [Cu2+-BP10]. (Bottom) Lineweaver-Burk plot titrating catechol at different [kojic 
acid] ( 0 mM, ●; 0.025 mM,○; 0.05 mM, ▼; 0.10 mM, ∆) (Table) The effects of 
[kojic acid] on Vmax and Km, in addition to the Ki for competitive inhibition. 
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[Cyanide] mM Km (mM) Vmax (mM/s) 
0.00 0.132 ± .008 (8.96 ± 0.16) x 10-6 
5.0 x 10-4 0.166 ± .005 (8.59 ± 0.08) x 10-6  
2.0 x10-3 0.211 ± .034 (6.22 ± 0.33) x 10-6 
3.5 x 10-3 0.223 ± .035 (4.06 ± 0.21) x 10-6  
Ki = (1.4 ± 1.7) x10-3 mM  |  Kis = (6.3 ± 4.7) x10-3 mM 
 
Figure 2-18:  Cyanide Inhibition in the presence of O2. (Top) Cyanide titration into 
constant [catechol] and [Cu2+-BP10]. (Bottom) Lineweaver-Burk plot titrating 
catechol at different [cyanide] ( 0 mM●, 0.5µM ∆, 2.0 µM ○, 3.5 µM ▼) (Table) 
The effects of [cyanide] on Vmax and Km, in addition to the Ki (Interaction with 
free E) and Kis (interaction with the ES complex) for mixed type inhibition. 
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[Inhibitor] mM Km (mM) Vmax (mM/s) 
0.0 0.496 ±.052 (6.31 ± 0.19) x 10-6 
1.5 x 10-3 0.522 ± .034 (3.57 ± 0.08) x 10-6  
3.0 x 10-3 0.764 ± .137 (3.17 ± 0.23) x 10-6  
Ki= 3.03x10-3 mM               |                 Kis= 1.45x10-3 mM 
Figure 2-19: Cyanide Inhibition in the presence of H2O2. (Top) Titrating 
cyanide into fixed [Catechol], [Cu2+-BP10], and [H2O2]=.7mM. (Bottom) 
Lineweaver-Burk plot titrating H2O2 at different [cyanide] ( 0 mM,●; 1.5 
µM, ○; 3.0 µM, ▼) while keeping [catechol] at saturating conditions. (Table) 
The effects of [cyanide] on Vmax and Km, in addition to the Ki for 
noncompetitive inhibition. 
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binding.  The third cyanide inhibition experiment involved H2O2 at saturating conditions 
while titrating catechol (Figure 2-15). The results clearly represents uncompetitive 
inhibition of cyanide against catechol.  An uncompetitive inhibitor binds only to the ES 
complex. Since cyanide is considered an oxygen mimic, the results suggest that oxygen 
(cyanide) would bind to the active center after catechol is bound to form the Cu2+-BP10-
catechol complex. 
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[Inhibitor] mM Km (mM) Vmax  (mM/s) 
0.0 1.06 ± 0.28 (1.24 ± 0.16) x10-5  
1.5 x 10-3 .590 ± 0.085 (5.19 ± 0.94) x 10-6 
3.0 x 10-3 .375 ± 0.053 3.27 ± 0.15) x10-6  
Ki = 1.64 x 10-3 mM 
 
Figure 2-20: Cyanide Inhibition in the presence of H2O2. Lineweaver-Burk plot 
titrating catechol at different [cyanide] ( 0 mM●, 1.5 µM ○, 3.0 µM ▼) while keeping 
[H2O2] at saturating conditions (8mM). (Table) The effects of [cyanide] on Vmax and 
Km, in addition to the Ki. 
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Closing Remarks 
 The metzinicin motif found in BP10 has shown to bind Cu2+ and form a Type-III 
Cu-center.  The complex is relatively active in comparison to the background rate of 
catechol and phenol oxidation.  Furthermore, it shows that H2O2 can enhance the reaction 
and serves as the second substrate in a bisubstrate reaction.  From the Hanes analysis, 
catechol seems to have no effect on H2O2 binding, while H2O2 increases the affinity for 
catechol slightly.  The catechol binding to the free E was confirmed by the kojic acid 
inhibition.  Cyanide inhibitions confirmed that oxygen is involved in the reaction and that 
cyanide binds only after catechol binding. 
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Chapter Three 
 
 Alzheimer’s Disease and Natural Antioxidants 
 
 
 
Introduction/ Rationale  
 
Of neurodegenerative diseases, the most prevalent is Alzheimer’s disease (AD).  
Although the past decade has made significant progress on the cause of the disease, it still 
remains somewhat of a mystery.  Of the many hypotheses proposed, the common link 
seems to be amyloid β-peptide (Aβ).1  This short peptide varies in length following 
secreatase cleavage of the amyloid precursor protein (APP).1  In general, shorter more 
soluble fragments are considered to be nonamyloidgenic, while longer hydrophobic 
fragments are considered the cause or effect of AD.1   Along with a microtubule 
stabilizing tau protein, longer fragments of Aβ have shown to accumulate, forming 
plaques in the brain.1  Studies have shown these plaques to be responsible for alterations 
in normal brain function, such as abnormal Ca2+ homeostasis and production of H2O2.1,2,3  
Furthermore, postmortem studies have revealed the presence of redox active metal (e.g. 
Cu2+) present in the plaques.4  The presence of this seemingly misguided metal has fueled 
the hypothesis of reactive oxygen species (ROS) as a major component of neuronal cell 
loss.  In addition, studies have shown Aβ to bind metal with a relativity high affinity 
within the first 14 amino acids of the peptide.5 
This study presents soluble fragments of Cu2+-bound Aβ as highly redox active 
complexes.  Compassions between fragments of Aβ containing the amino acids believed 
to start dimerization will be examined.6  This will include the effect of ROS on the redox 
activity of Cu2+-Aβ toward the neurotransmitter dopamine. In addition, natural 
antioxidants (e.g. flavonoids and vitamins) will be used to inhibit this AD-related redox 
 62
chemistry.  This will allow for further infancies on the possible beneficial effect of 
numerous antioxidants and the identification of structural moieties that enhance the 
overall antioxidant activity.    
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Figure (3-1) Purposed mechanism for polyphenol oxidation by Cu2+-Aβ.7  
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Experimental 
 
 
Chemicals and Materials for Metal Titrations and Kinetics Assays 
 
 The Aβ peptides (16 and 20 amino acid) were synthesized and purchased from the 
University of South Florida Peptide Center.  The identity of the peptides 
(DAEFR5HDSGY10EVHHQ15KLVFF20 and DAEFR5HDSGY10EVHHQ15K) were 
confirmed with a Bruker matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometer.  The buffer used in all assays is 100 mM HEPES at 
pH 7.4 or 7.0, with small amount of chlex resin to demetalize the solution.  EDTA was 
used in cleaning glass/plastic ware prior to usage, in order to prevent metal 
contamination.  Deionized water of 18 MΩ was obtained from a Milli Q system 
(Millipore, Bedford, MA) and used for all cleaning and for preparation of stocks 
solutions. CuSO4 and  CaCl2 were used for all experiments.  All kinetic studies were run 
using a Varian CARY50 Bio-UV-Vis spectrophotometer. 
 
Peptide Preparation  
 
The molar absorptivity was determined by monitoring the absorbance of known 
concentrations of peptide dissolved in water at 280nm for the aromatic amino acids.  
Metal derivatives were prepared by the addition of a known concentration of metal to 
achieve a 1:1 metal to peptide ratio.  Since Aβ tends to coagulate, fresh peptide stocks 
were prepared and used within 24 hours. 
 
Dopamine and Flavonoid Oxidation assays 
 
Using a constant Cu2+-Aβ concentration (1-6µM) with a 1:1 Cu-to-peptide ratio, 
various substrate concentrations were assayed.  The final volume of each assay is 1 mL at 
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pH 7.4 100mM HEPES and 298 K. The concentration of MBTH was kept in proportion 
with substrate concentration. Dopamine were varied from 0.1-2.5 mM and the MBTH-o-
quinone product was monitored at 510 nm for 3-5 mins. Similar assays were constructed 
for epicatechin (EC), epigallocatechin gallate (EGCG), and epigallocatehin (EGC) and 
were monitored at their respective λmax (460nm , 465nm, and 460 nm).  
Hydrogen peroxide (H2O2) titration were performed with fixed catalyst and 
saturating conditions of substrate. The conditions were similar to non-H2O2 assays 
described above. H2O2 varied and the dopamine/EC/EGC/EGCG-MBTH product was 
monitored at their respective absorbencies. Additionally, experiments were preformed 
that varied substrate at a fixed catalyst and H2O2 concentration. These data were then 
fitted to the Hanes analysis to determine apparent and intrinsic dissociation constants. 
Molar Absorptivity  
The Molar Absorptivity (ε) was calculated by oxidizing a known concentration of 
substrate with tyrosinase with excess MBTH at the pH 7.4 100mM HEPES buffer.  The  ε  
for EGCG was found by the combination of value for EGC and gallic acid.  
 
Inhibition Experiments 
 
Conditions for inhibition experiments consisted of µM Cu2+-Aβ, pH 7.4 or 7.0 
HEPES 100 mM buffer, 293 K, and 1 ml total volume.  The inhibitors used were 
Substrates (pH 7.4) Dopamine EC EGC EGCG 
ε (M-1 cm-1) 10095 10040 7159 7665 
Wavelength (nm) 510  460  460  465  
 
Table 3-1:  Molar Absorptivity values for neurotransmitter and flavonoids 
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quercetin, fisetin, taxifolin, ascorbic acid, and pyridoxamine.  For all inhibitors a Dixon 
plot was obtained by titrating inhibition into a fixed concentrations of dopamine, MBTH, 
and Cu2+-Aβ.  Then oxidation rates at different [dopamine] were determined in a fixed [I] 
and [Cu2+-Aβ] to obtain the Lineweaver-Burk plots. Inhibition constants were determined 
from inhibition equations from Chapter 2. 
Attenuation of inhibition was monitored by titrating Ca2+ into a fixed 
concentration of fisetin, dopamine, and Cu2+-Aβ.  Oxidation rate of dopamine was then 
determined at fixed concentration of fisetin, Cu2+-Aβ, and Ca2+to obtain kinetic 
parameters. 
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Results and Discussion 
 
 
Green Tea  
 
Dopamine is a catechol containing neurotransmitter found extensively throughout 
the body.  Like other neurotransmitters, dopamine is used to amplify and regulate signals 
to dopamine receptors.  An alteration in levels of dopamine (e.g. oxidation) is in general a 
hallmark of several neurodegenerative diseases.7  Alzheimer’s disease (AD) is associated 
with degradation of normal brain function which includes altered levels of 
neurotransmitters, influx of Ca2+, and accumulation of protein fragments.1,2  The results in 
figure 3-2 and 3-3 indicated Cu2+-Aβ1-16 and Cu2+-Aβ1-20 significantly accelerate aerobic 
oxidation of dopamine in terms of kcat relative to auto-oxidation rate constant ko = 1.59 x 
10-8. Furthermore, the additional 4 amino acids of Cu2+-Aβ1-20 seem to have a negligible 
effect on dopamine oxidation.  Through metal ion reduction, reports have indicated the 
production of H2O2 by metallo-Aβ.2 The results in figure (3-5) and (3-6) indicated that 
H2O2 significantly increases the rate of oxidation of dopamine.  The oxidation rate 
dependent on H2O2 eventually plateaus, concluding H2O2 binds Cu2+-Aβ and is turned 
over.   Since both dopamine and H2O2 are considered substrates for Cu2+-Aβ1-16 and Cu2+-
Aβ1-20 , the data can be fitted to a bisubstrate random-binding equation to obtain both 
apparent and intrinsic dissociation constants Kapp and Km. (Table 3-2).   
The oxidation and generation of ROS in AD brains have suggested possible 
benefit from the consumption of foods with high antioxidant content.9  A class of 
compounds reported to have antioxidant, antiradical, and influence on APP processing 
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are the green tea catechins (GTC).10,11  The three GTCs were shown to be substrates for 
both  Cu2+-Aβ1-16 and Cu2+-Aβ1-20 (Figures 3-2 – 3-4). 
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Cu2+-Aβ16 Dopamine EC EGCG 
Km (mM) 0.269 ± 0.033 0.830 ± 0.095 0.215 ± 0.012 
Vmax (mM/s) (1.45 ± 0.06) x 10-5 (1.08 ± 0.05) x10-5  (2.73 ± 0.05) x 10-5
kcat (s-1) 4.83 x 10-3 3.60x10-3 9.10x10-3 
kcat / Km (mM-1 s-1) 0.0180 4.34x10-3 .0423 
 
Figure 3-2:  Saturation kinetic profile for the oxidation of dopamine (▼), epicatechin 
(EC) (○), and epigallocatechin gallate (EGCG) (●) using Cu2+-Aβ16 (3 µM) at 100 mM 
HEPES pH 7.4, 298K.  Table includes kinetic parameters for dopamine, EC, and EGCG 
oxidation by Cu2+-Aβ16. 
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Cu2+-Aβ20 Dopamine EC EGCG 
Km (mM) 0.214 ± .050 0.302 ± 0.016 0.310 ± 0.053  
Vmax (mM/s) (3.26 ± 0.22) x 10-5 (2.66 ± 0.05) x10-5  (9.52 ± 0.52) x 10-5
kcat (s-1) 4.66x10-3 3.80x10-3 .0136 
kcat / Km (mM-1 s-1) 0.0218 0.0126 0.0439 
 
Figure 3-3:  Saturation kinetic profile for the oxidation of dopamine (○), epicatechin (EC) 
(▼), and epigallocatechin gallate (EGCG) (●) using Cu2+-Aβ20 (7 µM) at 100 mM HEPES 
pH 7.4 298K.  Tables include kinetic parameters for dopamine, EC, and EGCG oxidation by 
Cu2+-Aβ20. 
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EGC Cu2+-Aβ16 Cu2+-Aβ20 
Km (mM) 1.22 ± 0.28 8.91 ± 0.30 
Vmax (mM/s) (3.42 ± 0.35) x 10-4  (3.30 ± 0.43) x 10-4  
kcat (s-1) .114 .0825 
kcat / Km (mM-1 s-1) .0934 .00926 
 
Figure 3-4: oxidation of epigallocatechin (EGC) by Cu2+-Aβ20 (○)(4µM) and Cu2+-
Aβ16 (●)(3µM) at 100mM HEPES pH 7.4, 293 K. Table includes kinetic 
parameters for EGC oxidation by Cu2+-Aβ16,20. 
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Additionally, the effect of H2O2 on Cu2+-Aβ catalysis was also monitored to obtain both 
apparent (Kapp) and intrinsic (Km ) affinity constants. (Figure 3-5, 3-6 and Table 3-2).  The 
Kapp/Km ratio can reveal details on the effect one substrate have on the affinity of other. 
Ratios above unity indicate one substrate decreases the affinity for the other, while those 
above unity indicate the opposite.  For dopamine, EC, and EGCG, H2O2 seems to have 
little effect on the binding (close to unity).  On the contrary, dopamine, EC, and EGCG 
seem to slightly increase the binding affinity for H2O2.   
 In addition to catechins, green tea is also an excellent source of ascorbic acid 
(AsA) and vitamin B6 (B6).  Studies have shown both to serve as excellent antioxidants in 
addition to other vital roles in the human body.  As shown in Figure (3-7,3-8), AsA is an 
excellent mixed type inhibitor for Cu2+-Aβ1-16 and Cu2+-Aβ1-20 toward dopamine 
oxidation.  The most likely explanation is AsA may bind to the metal center and reduce 
Cu2+ to Cu+ thus preventing O2 from binding. Studies have shown AsA can increase the 
stability of GTCs, thus providing benefit by protecting antioxidants from premature 
oxidative breakdown.  The other component in green tea is one of three derivates of 
vitamin B6, pyridoxamine.  Pyridoxamine is a critical component needed by the body, 
used by some enzymes for the production of neurotransmitters.12 Furthermore, 
prydoxamine has been shown to inhibit ROS generated in the body.12  As shown in 
figures (3-9, 3-10) pyridoxamine is a competitive inhibitor.  The competitive inhibition 
pattern is most likely to be due to pyridoxamine weak affinity for Cu2+.12  This is further 
supported by the large Ki (in comparison to AsA).  
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Figure 3-5:  The effect of the concentration of H2O2 on the first-order rate 
constant kcat toward the Aβ 1-16 oxidation of Dopamine (●), Epicatechin (○), 
and epigallocatechin gallate (∆). 
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Figure 3-6:  The effect of the concentration of H2O2 on the first-order rate 
constant kcat toward the Aβ 1-20 oxidation of Dopamine (●), Epicatechin (○), 
and epigallocatechin gallate (▼). 
 72
 
 
 
 
 
 
 
 
 
 
 
Table 3-2: Hanes analysis to compare the apparent (Kapp) and intrinsic (Km) affinity 
constants of H2O2 on substrate binding and vise versa.  
 
 
 
 
 
 
 
 
 
 
Substrate Catalyst Kapp/Km Kapp(H) / Km(H) 
Dopamine Cu2+-Aβ16 .924 .228 
Dopamine Cu2+-Aβ20 1.39 1.18 
EGCG Cu2+-Aβ16 1.35 .771 
EGCG Cu2+-Aβ20 1.86 .924 
EC Cu2+-Aβ16 .554 .296 
EC Cu2+-Aβ20 1.43 .824 
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[Ascorbic Acid] mM Aβ1-16 Km (mM) Vmax (mM/s) 
0.0 0.211 ± .053 (3.75 ± 0.24) x 10-6 
3.0 x 10-4 0.372 ± .070 (3.25 ± 0.19) x 10-6 
1.2 x 10-3 0.560 ± .178 (2.00 ± 0.23) x 10-6 
Ki= 1.37 µM                                                         Kis= .302 µM 
Figure 3-7: Inhibition of Cu2+-Aβ1-16 by ascorbic acid (AsA). (Top) AsA titration 
into fixed [Cu2+-Aβ1-16] , 1 mM Dopamine, 1 mM MBTH.  (Bottom) Titrating 
dopamine at fixed concentrations of AsA.  Table includes effect of [AsA] on 
kinetic parameters including inhibition constants for mixed-type inhibition.  
Assays done at pH 7.4 100mM HEPES buffer , 293K. 
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[Ascorbic Acid] mM Aβ1-20 Km (mM) Vmax (mM/s) 
0.0 0.177 ± .016 (7.57 ± 0.16) x10-6 
5.0 x 10-4 0.248 ± .026 (7.58 ± 0.21) x 10-6  
2.0 x 10-3 0.237 ± .029 (5.84 ± 0.19) x 10-6  
3.0 x 10-3 0.523 ±.044 (5.61 ± 0.17) x10-6  
Ki = 8.59 µM                                                               Kis = 1.00 µM 
Figure 3-8: Inhibition of Cu2+-Aβ1-20 by ascorbic acid (AsA). (Top) AsA titration into fixed 
Cu2+-Aβ1-20, 1mM Dopamie, 1mM MBTH.  (Bottom) Titrating dopamine at fixed 
concentrations of AsA.  Table includes effect of [AsA] on kinetic parameters. including 
inhibition constants for mixed type inhibition.  Assays done at pH 7.4 100mM HEPES 
buffer , 293K. 
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[Pyridoxamine] mM Aβ 1-
20 
Km (mM) Vmax (mM/s) 
0.0  (●) 0.381 ± 0.063 (2.39 ± 0.14) x10-5 
0.5  (○) 0.590 ± 0.031 (2.74 ± 0.61) x10-5 
1.0  (▼) 0.959 ± 0.061 (3.31 ± 0.11) x10-5  
Ki= .911 mM 
 
Figure 3-9: Inhibition of Cu2+-Aβ1-20 by Pyridoxamine (B6). (Top) B6 titration into 
fixed [Cu2+-Aβ1-20], 1 mM Dopamie, 1mM MBTH.  (Bottom) Titrating dopamine at 
fixed concentrations of B6.  Table includes effect of [B6] on kinetic parameters, 
including inhibition constants for competitive inhibition.   Assays done at pH 7.4, 
100mM HEPES buffer , 293K.
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[Pyridoxamine] mM Aβ1-16 Km (mM) Vmax (mM/s) 
0.0 (●) 0.419 ± 0.020 (3.11 ± 0.05) x 10-5 
0.4 (○) 0.541 ± 0.015 (3.13 ± 0.04) x 10-5 
0.8 (▼) 0.746 ± 0.052 (3.37 ± 0.11) x 10-5  
Ki= 1.03 mM 
Figure 3-10: Inhibition of Cu2+-Aβ1-16 by Pyridoxamine (B6). (Top) B6 titration 
into fixed Cu2+-Aβ1-16, 1mM Dopamie, 1mM MBTH.  (Bottom) Titrating 
dopamine at fixed concentrations of B6.  Table includes effect of [B6] on kinetic 
parameters. including inhibition constants for competitive inhibition.   Assays 
done at pH 7.4 100mM HEPES buffer, 293K. 
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Quercetin, Fisetin, and Taxifolin 
There are over 6000 flavonoids which differ in both structure and bioactivity.13,14  
Studies have been done concerning the “best” structure for the binding of redox-active 
metal in addition to antioxidant and antiradical activity.13,14 The flavonoids used in this 
study are  structurally similar, differing only by the absence and presence of the enolate 
or β-keto-phenolate.  The results show quercetin, fisetin, and taxifolin to be competitive 
inhibitiors of Cu2+-Aβ oxidation of dopamine. Quercetin contains both the presence of 
the enolate or β-keto-phenolate and shows to be an excellent competitive inhibitor, 
yielding a Ki (4 µM) almost equivalent to the [Cu2+-Aβ] (Figure 3-11).  Fisetin does not 
contain the β-keto-phenolate, but it is near equivelant to querctin in terms of Ki. (Figure 
3-12, 3-13).  Taxifolin contains the β-keto-phenolate but is missing the double bond on 
the enolate.  Taxifolin shows also to be a competitive inhibitor with a Ki 100 times higher 
then quercetin or fisetin. (Figure 3-15, 3-16)  The results, in combination with the fact 
that catechins are substrates, reveal that the 3-hydroxy on the C-ring is required for 
inhibition.  Furthermore the presence of the enolate allows for a better affinity for Cu2+.  
To further distinguish between the β-keto-phenolate and enolate, fisetin was used in 
conjunction with Ca2+.  The Ca2+ titration in figure (3-14) reveal that Ca2+ attenuate the 
inhibition of fisetin oxidation of dopamine by Cu2+-Aβ16.  This result concludes that Ca2+ 
is binding in the same place as Cu2+ the enolate.    
The general mechanism for AD is believed to involve metal-centers ROS.  This 
study proposes the use of green tea components as suicide substrates and antioxidants for 
a possible way to slow the oxidation of neurotransmitters.  In addition, citrus flavonoids 
quecetin, fisetin, taxifolin have shown to be excellent inhibitors of both Cu2+-Aβ16 and 
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Cu2+-Aβ20.  The Ca2+ binding properties allude to certain flavonoids to serve as Ca2+ 
“sponge”, potentially reducing the influx of Ca2+ seen in AD.  The activity and inhibition 
of both the Cu2+-Aβ16 and Cu2+-Aβ20 conclude that the 4 amino acid differences make no 
significant contribution to activity.   
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[Quercetin] mM Aβ16 Km (mM) Vmax (mM/s) 
0 0.467 ± 0.053 (3.26 ±0.15) x 10-5 
2.0 x 10-3 0.699 ± 0.052 (3.59 ± 0.13) x10-5 
4.0 x 10-3 0.962 ± 0.082 (3.92 ± 0.18) x 10-5  
6.0 x 10-3 1.31 ± 0.16 (4.39 ± 0.29) x 10-5  
8.0 x 10-3 1.57 ± 0.12 (4.32 ± 0.19) x 10-5 
Ki= .004 mM 
Figure 3-11: Quercetin inhibition of Cu2+-Aβ1-16 oxidation of dopamine. (Top) 
Quercetin titration into fixed [Cu2+-Aβ1-16], [Dopamine]. [MBTH].  (Bottom) Titrating 
dopamine at fixed concentrations of quercetin.  Table includes effect of [Quercetin] on 
kinetic parameters including inhibition constants for competitive inhibition.  Assays 
done at pH 7.0 100mM HEPES buffer , 293K. (●), .002(○), .004 (▼), .006(∆), 
.008mM (■) of inhibitor. 
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[Fisetin] mM Aβ1-20 Km (mM) Vmax (mM/s) 
0 0.307 ± 0.039 (9.22 ± 0.37) x10-6 
1.25 x 10-2 0.756 ± 0.148 (8.12 ± 0.75) x10-6  
2.50 x 10-2 1.73 ± 0.35 (9.83 ± 0.13) x 10-6  
5.00 x 10-2 2.03 ± 0.78 (7.40 ± 0.19) x10-6 
Ki= .009 mM 
Figure 3-12: Fisetin inhibition of Cu2+-Aβ1-20 oxidation of dopamine. (Top) Fisetin 
titration into fixed [Cu2+-Aβ1-16], [Dopamine]. [MBTH].  (Bottom) Titrating 
dopamine at fixed concentrations of fisetin.  Table includes effect of [fisetin] on 
kinetic parameters including inhibition constants for competitive inhibition. 
Assays done at pH 7.4, 0 mM (●), .0125(○), .025 (▼), .05(∆), of inhibitor.  
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 [Fisetin] mM Aβ1-16 Km (mM) Vmax (mM/s) 
0.00 0.271 ± 0.040 (8.71 ± 0.39) x 10-6 
1.25 x 10-2 0.830 ± 0.176 (7.97 ± 0.83) x 10-6 
2.50 x 10-2 1.31 ± 0.34 (8.31 ± 1.24) x 10-6 
5.00 x 10-2 2.32 ± 0.69 (7.59 ± 1.55) x10-6 
Ki= .007 mM 
Figure3-13: Fisetin inhibition of Cu2+-Aβ1-16 oxidation of dopamine. (Top) Fistein 
titration into fixed [Cu2+-Aβ1-16], [Dopamine]. [MBTH].  (Bottom) Titrating 
dopamine at fixed concentrations of fistein.  Table includes effect of [fistein] on 
kinetic parameters including inhibition constants for competitive inhibition. Assays 
done at pH 7.4, 0 mM (●), .0125(○), .025 (▼), .05(∆),of inhibitor. 
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Fisetin - Ca2+ Aβ1-16 Fistein 0 mM Fistein .025 mM Fistein .025 mM Ca2+ 
Km (mM) 0.271 ± 0.040 1.310 ± 0.337 0.806 ± 0.088 
Vmax (mM/s) (8.71 ± 0.39) x 10-6  (8.32 ± 1.24) x 10-6  (8.73 ± 0.41) x 10-6 
kcat s-1 0.003 0.003 0.003 
kcat /Km (mM-1 s-1) 0.011 0.002 0.004 
Figure 3-14: Ca2+ effect on Fistein inhibition of Cu2+-Aβ1-16 oxidation of dopamine.  (Top) 
Ca2+ titration in fixed [Cu2+-Aβ1-16], [Dopamine], and [Fisetin].  (Bottom) Dopamine 
titrations without fisetin (▲), with fisetin (○), and with fisetin + Ca2+ ([Ca2+] = 30 mM)(●). 
Table includes kinetic parameters. 
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[Taxifolin] mM Aβ1-16 Km (mM) Vmax (mM/s) 
0.00 0.271 ± 0.040 (8.71 ± 0.39) x 10-6 
0.16 0.392 ± 0.075 (8.38 ± 0.57) x 10-6 
0.32 0.670 ± 0.149 (9.66 ± 0.97) x 10-6 
0.64 1.23 ± 0.282 (1.14 ± 0.15) x10-5  
Ki = 0.216 mM 
Figure3-15: Taxifolin inhibition of Cu2+-Aβ1-16 oxidation of dopamine. (Top) Taxifolin 
titration into fixed [Cu2+-Aβ1-16], [Dopamine]. [MBTH].  (Bottom) Titrating dopamine 
at fixed concentrations of taxifolin.  Table includes effect of [Taxifolin] on kinetic 
parameters including inhibition constants for competitive inhibition. Assays done at 
pH 7.4, 0 (■), .16 (●), .32 (○), .64 mM(▼),of inhibitor. 
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[Taxifolin] mM Aβ1-20 Km (mM) Vmax (mM/s) 
0.00 0.290 ± .0585 (1.19 ± 0.08) x 10-5 
0.16 0.331 ± .0663 (1.15 ± 0.08) x 10-5  
0.32 0.539 ± .102 (1.10 ± 0.09) x 10-5 
0.64             0.729 ± .150 (1.12 ± 0.11) x 10-5 
Ki= 0.372 mM 
Figure3-16: Taxifolin inhibition of Cu2+-Aβ1-20 oxidation of dopamine. (Top) Taxifolin 
titration into fixed [Cu2+-Aβ1-20], [Dopamine]. [MBTH].  (Bottom) Titrating dopamine 
at fixed concentrations of taxifolin.  Table includes effect of [Taxifolin] on kinetic 
parameters including inhibition constants for competitive inhibition. Assays done at 
pH 7.4, 0 (■), .16 (●), .32 (○), .64 mM(▼),of inhibitor. 
 85
Closing Remarks 
With plaques composed of Aβ in addition to redox active metal, the results 
indicate their combination can result in oxidative damage. As shown, different forms of 
metallo-Aβ can oxidative neurotransmitters which may be a cause or effect of AD.  This 
thesis focuses on the possible use of natural antioxidants to slow or inhibit this oxidative 
damage.  Flavonoids have been studied extensively and are considered to provide 
therapeutic effect for numerous diseases.  Here, the GTCs were shown to be oxidized and 
can potentially serve as suicide substrates.  In addition vitamins AsA and B6  were shown 
to inhibit the metallo-Aβ redox chemistry, possibly by reducing or chelating the metal. 
This study extents into the debate over the “best” flavonoid, by examining the properties 
of several common moieties.  The GTCs, quercetin, fisetin, and taxifolin all vary specific 
functional groups and through inhibition of metallo-Aβ can determine thoughts of most 
benefit.  The results indicate that the enolate is the most important in terms of metal 
chelation.  The absence of the β-keto-phenolate seems to have no effect on the inhibition, 
while the opposite it true for the 2-3 alkene.   
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